Marina Ciscar

RANKL inhibition spatially rewires the microenvironment of luminal breast cancer

Mario Rodriguez-del-Collado, Andrea Vethencourt, Alexandra Barranco, Jaime Martínez de Villarreal et autres

es, us (code pays fourni par la source)

GALE-dependent glycoproteome remodelling is a determinant of oncogenic RAS transformation

Frauke Stoelting, Rita Vesce, César Rodríguez-Santana, Marina Ciscar et autres

de, dk, us, ca (code pays fourni par la source)

Iron and metabolic rewiring in cancer

Marina Ciscar, César Rodríguez-Santana, Naiara Santana-Codina

dk (code pays fourni par la source)

De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer

Huan Zhang, Naiara Santana-Codina, Qijia Yu, Clara Poupault et autres

us, dk (code pays fourni par la source)

Abstract P1-02-17: Rediscovering Denosumab: Immunomodulation of the Tumor Microenvironment in Early-Stage Breast Cancer through RANK Pathway Inhibition

Andrea Vethencourt, Eva M. Trinidad, Eduard Dorca, Teresa Soler-Monsó et autres

Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial

Andrea Vethencourt, Eva M. Trinidad, Eduard Dorca, Anna Petit et autres

es (code pays fourni par la source)

Abstract PS16-04: Denosumab as an enhancer of the immune infiltrate in hormone receptor-positive early breast cancer. Subgroup analysis from the D-Biomark window-of-opportunity clinical trial (NCT03691311)

Andrea Vethencourt, Eva M. Trinidad, Eduard Dorca, Anna Petit et autres

es (code pays fourni par la source)

Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.

Andrea Vethencourt, Eva M. Trinidad, Eduard Dorca, Anna Petit et autres

es, cu (code pays fourni par la source)

289P Results of the window-of-opportunity clinical trial D-BIOMARK: Study of biomarkers of the antitumor activity of denosumab and its role as a modulator of the immune response in early breast cancer

Andrea Vethencourt, Eva M. Trinidad, Eduard Dorca Duch, A. Petit et autres

es (code pays fourni par la source)

RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

Marina Ciscar, Eva M. Trinidad, Gema Pérez-Chacón, Mansour Alsaleem et autres

es, gb, us (code pays fourni par la source)

RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and a therapeutic target in patient-derived xenografts

Marina Ciscar, Eva M. Trinidad, Héctor Perez‐Montoyo, Mansour Alsaleem et autres

es, gb, us (code pays fourni par la source)

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

Adrián Sanz‐Moreno, Sònia Palomeras, Kim Pedersen, Beatriz Morancho et autres

de, es, ch, gb, nl (code pays fourni par la source)